Johnson & Johnson posts mixed 3Q results

Johnson & Johnson, continuing a tough year of declining revenue, posted a 29 percent drop in third-quarter earnings as it was hammered by plunging sales of its hepatitis C medicine and unfavorable currency exchange rates.

The healthcare bellwether’s results were also hurt by comparison to a year-ago when it had a $2 billion gain from selling a large diagnostics business.